GMP Warnings Reflect Firms’ Lack Of Commitment – Fabricant
This article was originally published in The Tan Sheet
Executive Summary
FDA inspectors continue to find good manufacturing practice violations of a basic, rather than technical, nature. The director of the agency’s Division of Dietary Supplement Programs hammered the point home to an industry audience May 2.
You may also be interested in...
ForMor Challenges FDA On Own-Label Supplement GMP Stance
ForMor contests a warning letter from FDA stating that as an own-label distributor, the firm is subject to both packager and labeler GMP requirements. The firm says it is only a “holder” of finished products and FDA bases its warning on the GMP rule preamble, not the actual rule.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.